A
Albrecht Kretzschmar
Researcher at Charité
Publications - 71
Citations - 2320
Albrecht Kretzschmar is an academic researcher from Charité. The author has contributed to research in topics: Capecitabine & Oxaliplatin. The author has an hindex of 19, co-authored 62 publications receiving 2002 citations. Previous affiliations of Albrecht Kretzschmar include Ruhr University Bochum & Humboldt University of Berlin.
Papers
More filters
Journal ArticleDOI
Survival advantage for irinotecan versus best supportive care as second-line chemotherapy in gastric cancer--a randomised phase III study of the Arbeitsgemeinschaft Internistische Onkologie (AIO).
Peter C. Thuss-Patience,Albrecht Kretzschmar,D. Bichev,Tillman Deist,Axel Hinke,Kirstin Breithaupt,Yasemin Dogan,Bernhard Gebauer,Guido Schumacher,Peter Reichardt +9 more
TL;DR: Irinotecan as second-line chemotherapy significantly prolongs overall survival compared to BSC in the studied pts and can now be considered as a proven treatment option for metastatic or locally advanced gastric cancer.
Journal ArticleDOI
Phase III Study of Capecitabine Plus Oxaliplatin Compared With Fluorouracil and Leucovorin Plus Oxaliplatin in Metastatic Colorectal Cancer: A Final Report of the AIO Colorectal Study Group
Rainer Porschen,Hendrik Tobias Arkenau,S. Kubicka,Richard Greil,Thomas Seufferlein,W. Freier,Albrecht Kretzschmar,Ullrich Graeven,Axel Grothey,Axel Hinke,Wolff Schmiegel,Hans Joachim Schmoll +11 more
TL;DR: CAPOX resulted in a slightly inferior efficacy than FUFOX, and the best estimate of the HR of 1.17 was within the prespecified equivalence range, however, a relevant inferiority cannot be excluded.
Journal ArticleDOI
Dalteparin for prevention of catheter-related complications in cancer patients with central venous catheters: final results of a double-blind, placebo-controlled phase III trial
Meinolf Karthaus,Albrecht Kretzschmar,H. Kröning,M. Biakhov,D. Irwin,Norbert Marschner,C. Slabber,George Fountzilas,A. Garin,N.G.F. Abecasis,W. Baronius,Guenther G. Steger,T. Südhoff,C. Giorgetti,Peter Reichardt +14 more
TL;DR: Dalteparin prophylaxis did not reduce the frequency of thromboembolic complications after CVC implantation in cancer patients and was demonstrated to be safe over 16 weeks of treatment in these patients.
Journal ArticleDOI
Harm or benefit of hormonal treatment in metastatic low-grade endometrial stromal sarcoma: single center experience with 10 cases and review of the literature.
Daniel Pink,T. Lindner,Alicia Mrozek,Albrecht Kretzschmar,Peter C. Thuss-Patience,Bernd Dörken,Peter Reichardt +6 more
TL;DR: Patients with a previous history of low-grade ESS should not be treated with estrogens or tamoxifen, but MPA and letrozole, in particular, are highly effective and lead to sustained disease control in most cases.
Journal ArticleDOI
Docetaxel and Continuous-Infusion Fluorouracil Versus Epirubicin, Cisplatin, and Fluorouracil for Advanced Gastric Adenocarcinoma: A Randomized Phase II Study
Peter C. Thuss-Patience,Albrecht Kretzschmar,Michael Repp,Dorothea Kingreen,Dirk Hennesser,Simone Micheel,Daniel Pink,Christian W. Scholz,Bernd Dörken,Peter Reichardt +9 more
TL;DR: Compared with ECF, the dual combination of DF shows promising efficacy and may be an alternative treatment option that avoids cisplatin.